Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Caribou Biosciences (CRBU) and Boston Scientific (BSX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report), Caribou Biosciences (CRBU – Research Report) and Boston Scientific (BSX – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amgen (AMGN)
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Amgen, with a price target of $309.00. The company’s shares closed last Tuesday at $338.59, close to its 52-week high of $346.85.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $356.76, implying a 4.5% upside from current levels. In a report issued on January 20, Bernstein also downgraded the stock to Hold with a $335.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Caribou Biosciences (CRBU)
In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Caribou Biosciences, with a price target of $6.00. The company’s shares closed last Tuesday at $1.56, close to its 52-week low of $0.88.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $9.00 average price target, which is a 478.8% upside from current levels. In a report issued on February 2, Clear Street also initiated coverage with a Buy rating on the stock with a $13.00 price target.
Boston Scientific (BSX)
In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Boston Scientific, with a price target of $115.00. The company’s shares closed last Tuesday at $91.62.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $122.00, implying a 33.3% upside from current levels. In a report issued on January 26, Evercore ISI also initiated coverage with a Buy rating on the stock with a $112.00 price target.
